TB 003
Alternative Names: TB-003; TB-003BLatest Information Update: 12 Jan 2026
At a glance
- Originator Therabene
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 9 degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 22 Oct 2025 Pharmacodynamics and adverse event data from a preclinical study in Solid tumours and Haematological malignancies presented at the ACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 22 Feb 2024 Preclinical trials in Haematological malignancies in USA (Intraperitoneal) Prior to February 2024
- 22 Feb 2024 Preclinical trials in Solid tumours in USA (Intraperitoneal) Prior to February 2024